Editorially independent content, supported with advertising
10.02.25
How should retina specialists reframe their approach to GA therapy? In the final episode of this New Retina Radio miniseries, moderator John Kitchens, MD joins experts Margaret Chang, MD, MS; David Eichenbaum, MD; and Ferhina Ali, MD, MPH, to explore how to shift doctor mindsets from restoring vision to preserving it. The panel discusses challenges of counseling without clear imaging endpoints, the role of AI and microperimetry in demonstrating treatment value, and why some providers remain hesitant to adopt complement inhibitors. They also consider lessons from past therapies, tissue preservation as a meaningful endpoint, and how innovation may soon deliver more potent options.
Editorially independent content, supported by Astellas Pharma.
10.02.25
Keeping Patients at the Center of GA Therapy: Social Impact and Early InterventionJohn Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD
Editorially independent content, supported by Astellas Pharma.
10.02.25
Keeping Patients at the Center of GA Therapy: Patient Education and Setting ExpectationsJohn Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD
Editorially independent content, supported by Astellas Pharma.
10.02.25
Keeping Patients at the Center of GA Therapy: Dosing Schedules, AREDS Vitamins, and PhotobiomodulationJohn Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD
Editorially independent content, supported by Astellas Pharma.
10.02.25
Keeping Patients at the Center of GA Therapy: Preserving Vision vs Restoring VisionJohn Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD
Editorially independent content, supported by Astellas Pharma.
12.12.24
GA Options in Clinical Therapy: Which Patients Are a Fit for GA Treatment?John Kitchens, MD; Saradha Chexal, MD; and Geeta Lalwani, MD
Editorially Independent content supported by Astellas.
10.28.24
GA Options in Clinical Therapy: Why Aren't Doctors Embracing Complement Inhibition?John Kitchens, MD, Miguel Busquets, MD, and Esther Kim, MD
Editorially Independent content supported by Astellas.
05.10.24
GA Options in Clinical Therapy, Part 1: Patient Selection and Treatment StrategiesDavid RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD
Editorially Independent content supported by Astellas.
05.10.24
GA Options in Clinical Therapy, Part 2: Real-World Cases in GADavid RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD
Editorially Independent content supported by Astellas.